Micronised tissue allografts - MiMedx

Drug Profile

Micronised tissue allografts - MiMedx

Alternative Names: Amniofix®; Amniotic cell therapy - MiMedix; Dehydrated human amnion/chorion allograft; Dehydrated human amnion/chorion membrane; Dehydrated human amniotic membrane; Dehydrated human amniotic membrane micronised; Human amniotic membrane allograft - MiMedix; Micronised dehydrated human amniotic membrane

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MiMedx
  • Class Anti-inflammatories; Cell therapies; Tissue extracts
  • Mechanism of Action Cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plantar fasciitis; Tendinitis
  • Phase II Osteoarthritis; Wounds
  • Clinical Phase Unknown Shoulder injuries
  • Preclinical Ischaemia

Most Recent Events

  • 17 Nov 2017 Phase-IIb clinical trials in Knee Osteoarthritis (Injection)
  • 17 Oct 2017 MiMedx plans a phase IIb trial for Osteoarthritis in USA in the first quarter of 2018
  • 17 Oct 2017 US FDA approves IND application for phase IIb trial of micronised tissue allografts in Osteoarthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top